IP Library Granted Patent US 8,227,230
Granted Patent B2
US 8,227,230 · App. 13/080,692 · Granted Jul 24, 2012

Human lysosomal proteins from plant cell culture

Assignee: Protalix Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,227,230
App. No.
13/080,692
Granted
Jul 24, 2012
Kind
B2
Abstract

A device, system and method for producing glycosylated proteins in plant culture, particularly proteins having a high mannose glycosylation, while targeting such proteins with an ER signal and/or by-passing the Golgi. The invention further relates to vectors and methods for expression and production of enzymatically active high mannose lysosomal enzymes using transgenic plant root, particularly carrot cells. More particularly, the invention relates to host cells, particularly transgenic suspended carrot cells, vectors and methods for high yield expression and production of biologically active high mannose Glucocerebrosidase (GCD). The invention further provides for compositions and methods for the treatment of lysosomal storage diseases.

Claims (8)

1. A recombinant human glucocerebrosidase protein comprising an amino acid sequence as set forth in SEQ ID NO: 15.

2. The recombinant human glucocerebrosidase protein of claim 1 , being glycosylated with at least one exposed mannose residue.

3. The recombinant human glucocerebrosidase protein of claim 1 , further comprising at least one fucose residue having an alpha (1-3) glycosidic bond.

4. The recombinant human glucocerebrosidase protein of claim 1 , further comprising at least one core xylose residue.

5. The recombinant human glucocerebrosidase protein of claim 2 , being glycosylated with at least one core xylose residue and at least one fucose residue having an alpha (1-3) glycosidic bond.

6. The recombinant human glucocerebrosidase protein of claim 2 , wherein said glucocerebrosidase protein binds to a mannose receptor on a macrophage.

7. The recombinant human glucocerebrosidase protein of claim 6 , having an increased uptake in said macrophages, in comparison with the corresponding uptake of a mammalian cell-expressed glucocerebrosidase protein by said macrophages.

8. A pharmaceutical composition for treating Gaucher's disease comprising the recombinant human glucocerebrosidase protein of claim 1 and a pharmaceutically acceptable carrier, said pharmaceutical composition formulated for parenteral administration.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Sep 6, 2024
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT
To: PROTALIX LTD.
Reel/Frame 068856/0589 →
SECURITY INTEREST Recorded Sep 3, 2021
From: PROTALIX LTD.
To: WILMINGTON SAVINGS FUND SOCIETY, FSB
Reel/Frame 057383/0155 →
SECURITY INTEREST Recorded Dec 12, 2016
From: PROTALIX LTD.
To: WILMINGTON SAVINGS FUND SOCIETY, FSB
Reel/Frame 040708/0661 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 4, 2011
From: SHAALTIEL, YOSEPH; BAUM, GIDEON; BARTFELD, DANIEL; HASHMUELI, SHARON; LEWKOWICZ, AYALA
To: PROTALIX LTD.
Reel/Frame 026220/0209 →
Priority Claims (1)
IL 155588 · Apr 27, 2003 · national
Continuity (3)
Division 11790991 · Apr 30, 2007
Continuation In Part 10554387
Related Publication 20110250181A1 · Oct 13, 2011